Article By:
Rod Raynovich
Monday, July 1, 2024 10:35 AM EDT
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.